Literature DB >> 22748941

Common Alzheimer's Disease Research Ontology: National Institute on Aging and Alzheimer's Association collaborative project.

Lorenzo M Refolo1, Heather Snyder, Charlene Liggins, Laurie Ryan, Nina Silverberg, Suzana Petanceska, Maria C Carrillo.   

Abstract

Alzheimer's disease is recognized as a public health crisis worldwide. As public and private funding agencies around the world enhance and expand their support of Alzheimer's disease research, there is an urgent need to coordinate funding strategies and leverage resources to maximize the impact on public health and avoid duplication of effort and inefficiency. Such coordination requires a comprehensive assessment of the current landscape of Alzheimer's disease research in the United States and internationally. To this end, the National Institute on Aging at the National Institutes of Health and the Alzheimer's Association developed the Common Alzheimer's Disease Research Ontology (CADRO) as a dynamic portfolio analysis tool that can be used by funding agencies worldwide for strategic planning and coordination.
Copyright © 2012 The Alzheimer's Association. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22748941     DOI: 10.1016/j.jalz.2012.05.2115

Source DB:  PubMed          Journal:  Alzheimers Dement        ISSN: 1552-5260            Impact factor:   21.566


  12 in total

1.  Cognitive Function Characterization Using Electronic Health Records Notes.

Authors:  Adrienne Pichon; Betina Idnay; Karen Marder; Rebecca Schnall; Chunhua Weng
Journal:  AMIA Annu Symp Proc       Date:  2022-02-21

2.  Alzheimer's disease drug development pipeline: 2020.

Authors:  Jeffrey Cummings; Garam Lee; Aaron Ritter; Marwan Sabbagh; Kate Zhong
Journal:  Alzheimers Dement (N Y)       Date:  2020-07-16

Review 3.  Developing the ATX(N) classification for use across the Alzheimer disease continuum.

Authors:  Harald Hampel; Jeffrey Cummings; Kaj Blennow; Peng Gao; Clifford R Jack; Andrea Vergallo
Journal:  Nat Rev Neurol       Date:  2021-07-08       Impact factor: 44.711

4.  Introducing Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring, an open access journal of the Alzheimer's Association.

Authors:  Peter J Snyder
Journal:  Alzheimers Dement (Amst)       Date:  2015-03-29

5.  Introducing Alzheimer's & Dementia: Translational Research & Clinical Interventions, an open access journal of the Alzheimer's Association.

Authors:  Lon S Schneider
Journal:  Alzheimers Dement (N Y)       Date:  2015-07-01

6.  Improving the Gene Ontology Resource to Facilitate More Informative Analysis and Interpretation of Alzheimer's Disease Data.

Authors:  Barbara Kramarz; Paola Roncaglia; Birgit H M Meldal; Rachael P Huntley; Maria J Martin; Sandra Orchard; Helen Parkinson; David Brough; Rina Bandopadhyay; Nigel M Hooper; Ruth C Lovering
Journal:  Genes (Basel)       Date:  2018-11-29       Impact factor: 4.096

Review 7.  The "rights" of precision drug development for Alzheimer's disease.

Authors:  Jeffrey Cummings; Howard H Feldman; Philip Scheltens
Journal:  Alzheimers Res Ther       Date:  2019-08-31       Impact factor: 6.982

Review 8.  A roadmap to develop dementia research capacity and capability in Pakistan: A model for low- and middle-income countries.

Authors:  Iracema Leroi; Nasim Chaudhry; Anna Daniel; Ross Dunne; Saima Eman; Nicolas Farina; Sana-E-Zehra Haidry; Nusrat Husain; Hussain Jafri; Salman Karim; Tayyeba Kiran; Murad Khan; Quratulain Khan; Shakil Jehangir Malik; Rakhshi Memon; Mowadat Hussain Rana; Ambily Sathish; Saima Sheikh; Asad Tamizudin; Sehrish Tofique; Zainab Zadeh
Journal:  Alzheimers Dement (N Y)       Date:  2019-12-28

9.  Gene Ontology Curation of Neuroinflammation Biology Improves the Interpretation of Alzheimer's Disease Gene Expression Data.

Authors:  Barbara Kramarz; Rachael P Huntley; Milagros Rodríguez-López; Paola Roncaglia; Shirin C C Saverimuttu; Helen Parkinson; Rina Bandopadhyay; Maria-Jesus Martin; Sandra Orchard; Nigel M Hooper; David Brough; Ruth C Lovering
Journal:  J Alzheimers Dis       Date:  2020       Impact factor: 4.472

10.  Drug Development for Psychotropic, Cognitive-Enhancing, and Disease-Modifying Treatments for Alzheimer's Disease.

Authors:  Jeffrey Cummings
Journal:  J Neuropsychiatry Clin Neurosci       Date:  2020-10-28       Impact factor: 2.198

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.